Published in Eur J Gastroenterol Hepatol on May 01, 2002
Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep (2008) 1.25
Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test. Dig Dis Sci (2005) 0.80
Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. World J Gastroenterol (2005) 0.79
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology (2011) 2.42
Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis (2011) 1.68
Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology (2006) 1.66
Factors related to fatigue in patients with cirrhosis before and after liver transplantation. Clin Gastroenterol Hepatol (2011) 1.53
Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology (2010) 1.51
Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet (2010) 1.43
Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol (2012) 1.29
Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. Hepatology (2013) 1.11
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology (2010) 1.09
Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology (2011) 1.09
Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. Scand J Gastroenterol (2006) 1.09
PACAP promotes neural stem cell proliferation in adult mouse brain. J Neurosci Res (2004) 1.08
CHD5 is required for neurogenesis and has a dual role in facilitating gene expression and polycomb gene repression. Dev Cell (2013) 1.06
Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. Liver Int (2007) 1.06
The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int (2006) 1.05
Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials. Am J Gastroenterol (2011) 1.03
Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration. J Cell Biol (2012) 1.01
Budd-Chiari syndrome in Sweden: epidemiology, clinical characteristics and survival - an 18-year experience. Liver Int (2008) 1.00
Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int (2011) 0.99
Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 0.98
High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med (2008) 0.98
Pax6-dependent boundary defines alignment of migrating olfactory cortex neurons via the repulsive activity of ephrin A5. Development (2006) 0.97
Ephrins negatively regulate cell proliferation in the epidermis and hair follicle. Stem Cells (2010) 0.95
The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol (2002) 0.95
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion (2003) 0.95
Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci (2002) 0.94
A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Ther Clin Risk Manag (2007) 0.94
Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol (2008) 0.94
The relationship between symptoms, body mass index, gastrointestinal transit and stool frequency in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol (2010) 0.93
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. World J Gastroenterol (2013) 0.91
Coronary artery disease in patients with liver cirrhosis. Dig Dis Sci (2009) 0.91
Cib2 binds integrin alpha7Bbeta1D and is reduced in laminin alpha2 chain-deficient muscular dystrophy. J Biol Chem (2008) 0.91
Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis. Clin Gastroenterol Hepatol (2008) 0.89
Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol (2010) 0.87
Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol (2008) 0.86
Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes. Scand J Gastroenterol (2009) 0.85
Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol (2012) 0.85
Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol (2007) 0.85
Occurrence of nighttime gastroesophageal reflux in disturbed and normal sleepers. Clin Gastroenterol Hepatol (2008) 0.85
Dominant strictures in patients with primary sclerosing cholangitis-revisited. Am J Gastroenterol (2004) 0.84
Type and etiology of liver cirrhosis are not related to the presence of hepatic encephalopathy or health-related quality of life: a cross-sectional study. BMC Gastroenterol (2008) 0.84
Intestinal permeability in cirrhotic patients with and without ascites. Scand J Gastroenterol (2006) 0.84
Altered postprandial glucose, insulin, leptin, and ghrelin in liver cirrhosis: correlations with energy intake and resting energy expenditure. Am J Clin Nutr (2007) 0.83
Inadequate use of proton-pump inhibitors in patients with liver cirrhosis. Eur J Gastroenterol Hepatol (2008) 0.83
Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis. J Hepatol (2009) 0.83
Lactulose treatment for hepatic encephalopathy, gastrointestinal symptoms, and health-related quality of life. Hepatology (2007) 0.82
Role of gastric sensorimotor dysfunction in gastrointestinal symptoms and energy intake in liver cirrhosis. Scand J Gastroenterol (2007) 0.81
Prevalence of gastrointestinal symptoms in patients with chronic obstructive pulmonary disease. Eur J Gastroenterol Hepatol (2008) 0.81
Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol (2008) 0.81
Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. Liver Int (2014) 0.81
Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol (2007) 0.80
Low-dose busulphan conditioning and neonatal stem cell transplantation preserves vision and restores hematopoiesis in severe murine osteopetrosis. Exp Hematol (2008) 0.80
Renal function and cognitive impairment in patients with liver cirrhosis. Scand J Gastroenterol (2007) 0.79
Pre-transplant renal impairment predicts posttransplant cardiac events in patients with liver cirrhosis. Transplantation (2014) 0.79
Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Clin Drug Investig (2008) 0.79
Pharmacokinetics of esomeprazole following varying intravenous administration rates. Basic Clin Pharmacol Toxicol (2005) 0.79
Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. Eur J Intern Med (2009) 0.79
Hepatic encephalopathy is related to anemia and fat-free mass depletion in liver transplant candidates with cirrhosis. Scand J Gastroenterol (2013) 0.79
Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies. Eur J Gastroenterol Hepatol (2005) 0.78
Long-term follow-up of patients with acute liver failure of indeterminate aetiology. Scand J Gastroenterol (2008) 0.78
Prevention of relapse of healed reflux esophagitis is related to the duration of intragastric pH > 4. J Clin Gastroenterol (2010) 0.78
Prevalence of pre-transplant electrocardiographic abnormalities and post-transplant cardiac events in patients with liver cirrhosis. BMC Gastroenterol (2014) 0.78
Impact of peri-transplant heart failure & left-ventricular diastolic dysfunction on outcomes following liver transplantation. Liver Int (2012) 0.78
Abstinence in patients with alcoholic liver cirrhosis: A follow-up study. Hepatol Res (2008) 0.78
Natural history of irritable bowel syndrome in women and dysmenorrhea: a 10-year follow-up study. Gastroenterol Res Pract (2012) 0.78
Severe injury to the small bowel associated with a short course of diclofenac. Scand J Gastroenterol (2008) 0.78
NCoR controls glioblastoma tumor cell characteristics. Neuro Oncol (2013) 0.77
Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction. Clin Pharmacokinet (2002) 0.77
Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy. World J Gastrointest Pharmacol Ther (2013) 0.77
Gastrointestinal symptoms in patients with cirrhosis: a longitudinal study before and after liver transplantation. Scand J Gastroenterol (2013) 0.77
Decreased postural adaptation in patients with phobic postural vertigo--an effect of an "anxious" control of posture? Neurosci Lett (2009) 0.76
Coronary artery disease in liver cirrhosis: does the aetiology of liver disease matter? J Hepatol (2009) 0.76
Cognitive dysfunction in liver cirrhosis: does hepatitis C virus play a role? J Gastroenterol (2008) 0.75
Intravenous Esomeprazole 40mg is Effective for the Control of Intragastric Acid Levels Whether Given as a 3-Minute Injection or a 30-Minute Infusion. Clin Drug Investig (2005) 0.75
[Difficult to stop primary sclerosing cholangitis]. Lakartidningen (2010) 0.75
Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response. J Pediatr Gastroenterol Nutr (2016) 0.75
Impact of cardiac dysfunction on health-related quality of life in cirrhotic liver transplant candidates. Eur J Gastroenterol Hepatol (2015) 0.75
[Medically unexplained vertigo]. Lakartidningen (2009) 0.75
[Helicobacter pylori can in rare cases be the cause of iron and vitamin B 12 deficiency. No increased risk of iron and vitamin B 12 deficiency due to proton pump inhibitors]. Lakartidningen (2004) 0.75